Inside J&J's Next Blockbuster Drug

Bloomberg
Loading video player...
Inside J&J's Next Blockbuster Drug
Bloomberg
Written by Bloomberg
Share

J&J's CFO Joseph Wolk joined Bloomberg Open Interest to talk about why its newly launched psoriasis pill could become one of its biggest drugs ever, already reaching 1,500 patients in just days. He explains how the company is avoiding risky mega-deals thanks to a strong pipeline, while confidently raising guidance and betting on long-term double-digit growth.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.